Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 220-227

  Heringlake, Stefan ^a   Hofdmann, Michael ^b   Fiebeler, Anette ^b   Manns, Michael P ^b   Schmiegel, Wolff ^a   Tannapfel, Andrea ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Aldo ketoreductase; Gene expression; Hepatocellular carcinoma; Representational difference analysis

Indexed keywords

ALDO KETOREDUCTASE 1; BIOLOGICAL MARKER; ENZYME; KI 67 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN; UNCLASSIFIED DRUG;

AKR1B10 GENE; ARTICLE; BILE DUCT CARCINOMA; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPRESENTATIONAL DIFFERENCE ANALYSIS; TECHNIQUE; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ALDEHYDE REDUCTASE; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 75349086165     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.005     Document Type: Article

References (52)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
3. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
4. Lazaridis K.N., and Gores G.J. Cholangiocarcinoma. Gastroenterology 128 (2005) 1655-1667
5. Blechacz B.R., and Gores G.J. Cholangiocarcinoma. Clin Liver Dis 12 (2008) 131-150
6. Yachimski P., and Pratt D.S. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 42 (2008) 178-190
7. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328 (1993) 1797-1801
8. Griffiths J., and Nix B. Modeling the hepatitis C virus epidemic in France using the temporal pattern of hepatocellular carcinoma deaths. Hepatology 35 (2002) 709-715
9. Sherman M. Alphafetoprotein: an obituary. J Hepatol 34 (2001) 603-605
10. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34 (2001) 570-575
11. Fujiyama S., Tanaka M., Maeda S., Ashihara H., Hirata R., and Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62 (2002) 57-63
12. Zhou L., Liu J., and Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12 (2006) 1175-1181
13. Spangenberg H.C., Thimme R., and Blum H.E. Serum markers of hepatocellular carcinoma. Semin Liver Dis 26 (2006) 385-390
14. Maruyama H., Yoshikawa M., and Yokosuka O. Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol 14 (2008) 1710-1719
15. Jin Y., and Penning T.M. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 47 (2007) 263-292
16. Takahashi M., Fujii J., Miyoshi E., Hoshi A., and Taniguchi N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int J Cancer 62 (1995) 749-754
17. Zeindl-Eberhart E., Jungblut P.R., Otto A., and Rabes H.M. Identification of tumor-associated protein variants during rat hepatocarcinogenesis. Aldose reductase. J Biol Chem 269 (1994) 14589-14594
18. Zeindl-Eberhart E., Jungblut P.R., Otto A., Kerler R., and Rabes H.M. Further characterization of a rat hepatoma-derived aldose-reductase-like protein-organ distribution and modulation in vitro. Eur J Biochem 247 (1997) 792-800
19. Saraswat M., Mrudula T., Kumar P.U., Suneetha A., Rao Rao T.S., Srinivasulu M., et al. Overexpression of aldose reductase in human cancer tissues. Med Sci Monit 12 (2006) CR525-CR529
20. Jin J., Krishack P.A., and Cao D. Role of aldo-keto reductases in development of prostate and breast cancer. Front Biosci 11 (2006) 2767-2773
21. Matz M., Shagin D., Bogdanova E., Britanova O., Lukyanov S., Diatchenko L., et al. Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic Acids Res 27 (1999) 1558-1560
22. Lisitsyn N., Lisitsyn N., and Wigler M. Cloning the differences between two complex genomes. Science 259 (1993) 946-951
23. Hubank M., and Schatz D.G. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 22 (1994) 5640-5648
24. Hubank M., and Schatz D.G. CDNA representational difference analysis: a sensitive and flexible method for identification of differentially expressed genes. Methods Enzymol 303 (1999) 325-349
25. Michiels L., Van Leuven F., van den Oord J.J., De Wolf-Peeters C., and Delabie J. Representational difference analysis using minute quantities of DNA. Nucleic Acids Res 26 (1998) 3608-3610
26. O'Neill M.J., and Sinclair A.H. Isolation of rare transcripts by representational difference analysis. Nucleic Acids Res 25 (1997) 2681-2682
27. Pastorian K., Hawel III L., and Byus C.V. Optimization of cDNA representational difference analysis for the identification of differentially expressed mRNAs. Anal Biochem 283 (2000) 89-98
28. Wang E., Miller L.D., Ohnmacht G.A., Liu E.T., and Marincola F.M. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 18 (2000) 457-459
29. von Stein O.D., Thies W.G., and Hofmann M. A high throughput screening for rarely transcribed differentially expressed genes. Nucleic Acids Res 25 (1997) 2598-2602
30. Franz O., Bruchhaus I.I., and Roeder T. Verification of differential gene transcription using virtual northern blotting. Nucleic Acids Res 27 (1999) e3
31. Tannapfel A., Geissler F., Köckerling F., Katalinic A., Hauss J., and Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J Pathol 187 (1999) 439-445
32. Tannapfel A., Wasner M., Krause K., Geissler F., Katalinic A., Hauss J., et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 91 (1999) 1154-1158
33. Tannapfel A., Engeland K., Weinans L., Katalinic A., Hauss J., Mössner J., et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 80 (1999) 1069-1074
34. Scuric Z., Stain S.C., Anderson W.F., and Hwang J.J. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 27 (1998) 943-950
35. Cao D., Fan S.T., and Chung S.S. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 273 (1998) 11429-11435
36. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarrays: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61 (2001) 2129-2137
37. Fukumoto S., Yamauchi N., Moriguchi H., Hippo Y., Watanabe A., Shibahara J., et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 11 (2005) 1776-1785
38. Breton J., Gage M.C., Hay A.W., Keen J.N., Wild C.P., Donnellan C., et al. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J Proteome Res 7 (2008) 1953-1962
39. Yoshitake H., Takahashi M., Ishikawa H., Nojima M., Iwanari H., Watanabe A., et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 17 (2007) 1300-1306
40. Yan R., Zu X., Ma J., Liu Z., Adeyanju M., and Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer 121 (2007) 2301-2306
41. Tammali R., Reddy A.B., Ramana K.V., Petrash J.M., and Srivastava S.K. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis 30 (2009) 799-807
42. Gallego O., Ruiz F.X., Ardèvol A., Domínguez M., Alvarez R., de Lera A.R., et al. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA 104 (2007) 20764-20769 [Epub 2007 Dec 17]
43. Crosas B., Hyndman D.J., Gallego O., Martras S., Parés X., Flynn T.G., et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 373 (2003) 973-979
44. Dragnev K.H., Rigas J.R., and Dmitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist 5 (2000) 361-368
45. Penning T.M. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 11 (2005) 1687-1690
46. Ma J., Yan R., Zu X., Cheng J.M., Rao K., Liao D.F., et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 283 (2008) 3418-3423 [Epub 2007 Dec 1]
47. Tian Q., Stepaniants S.B., Mao M., Weng L., Feetham M.C., Doyle M.J., et al. Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 3 (2004) 960-969 [Epub 2004 Jul 6]
48. Nie L., Wu G., and Zhang W. Correlation between mRNA and protein abundance in Desulfovibrio vulgaris: a multiple regression to identify sources of variations. Biochem Biophys Res Commun 339 (2006) 603-610 [Epub 2005 Nov 17]
49. Brockmann R., Beyer A., Heinisch J.J., and Wilhelm T. Posttranscriptional expression regulation: what determines translation rates?. PLoS Comput Biol 3 (2007) e57
50. Liu Z., Zhong L., Krishack P.A., Robbins S., Cao J.X., Zhao Y., et al. Structure and promoter characterization of aldo-keto reductase family 1 B10 gene. Gene 437 (2009) 39-44 [Epub 2009 Feb 21]
51. Teramoto R., Minagawa H., Honda M., Miyazaki K., Tabuse Y., Kamijo K., et al. Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta 1784 (2008) 764-772 [Epub 2008 Mar 5]
52. Martin H.J., Breyer-Pfaff U., Wsol V., Venz S., Block S., and Maser E. Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34 (2006) 464-470 [Epub 2005 Dec 28]